Literature DB >> 6171428

Comparison of human fibroblast and leukocyte interferon in the treatment of severe laryngeal papillomatosis in children.

U Göbel, W Arnold, V Wahn, J Treuner, H Jürgens, K Cantell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6171428     DOI： 10.1007/BF00441312

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  5 in total

1.  Interferon nomenclature.

Authors: 
Journal:  Nature       Date:  1980-07-10       Impact factor: 49.962

2.  Tubular forms of papova viruses in human laryngeal papilloma.

Authors:  W Arnold
Journal:  Arch Otorhinolaryngol       Date:  1979

3.  Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis.

Authors:  R Sundmacher; K Cantell; R Skoda; C Hallermann; D Neumann-Haefelin
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1978-11-30

4.  Interferon therapy in juvenile laryngeal papillomatosis.

Authors:  S Haglund; P G Lundquist; K Cantell; H Strander
Journal:  Arch Otolaryngol       Date:  1981-06

5.  Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.

Authors:  A Billiau; P De Somers; V G Edy; E De Clercq; H Heremans
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191
  5 in total
  3 in total

Review 1.  The clinical application of fibroblast interferon--an overview.

Authors:  A Billiau
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 2.  Interferons in the treatment of human papillomavirus diseases.

Authors:  P K Weck; J L Brandsma; J K Whisnant
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

Review 3.  The use of interferon-alpha in virus infections.

Authors:  N B Finter; S Chapman; P Dowd; J M Johnston; V Manna; N Sarantis; N Sheron; G Scott; S Phua; P B Tatum
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.